Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment

Reuters

Jun 16

Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment

Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited, has entered into a license agreement with NextCure, Inc. The agreement grants NextCure global rights, excluding the Greater China region, to SIM0505, a novel antibody-drug conjugate targeting CDH6 for the treatment of solid tumors. SIM0505 features Simcere Zaiming's proprietary TOPO isomerase 1 inhibitor, designed for broad anti-tumor activity with high systemic clearance. Preclinical studies have shown robust anti-tumor activity and a promising safety profile. Currently in Phase 1 clinical testing in China, NextCure plans to start clinical trials in the U.S. in the third quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2543767133"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543767133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543767133?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543767133","market":"us","top_or_hot":-1,"title":"Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited, has entered into a license agreement with NextCure, Inc. The agreement grants NextCure global rights, excluding the Greater China region, to SIM0505, a novel antibody-drug conjugate targeting CDH6 for the treatment of solid tumors. SIM0505 features Simcere Zaiming's proprietary TOPO isomerase 1 inhibitor, designed for broad anti-tumor activity with high systemic clearance. Preclinical studies have shown robust anti-tumor activity and a promising safety profile. Currently in Phase 1 clinical testing in China, NextCure plans to start clinical trials in the U.S. in the third quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited, has entered into a license agreement with NextCure, Inc. The agreement grants NextCure global rights, excluding the Greater China region, to SIM0505, a novel antibody-drug conjugate targeting CDH6 for the treatment of solid tumors. SIM0505 features Simcere Zaiming's proprietary TOPO isomerase 1 inhibitor, designed for broad anti-tumor activity with high systemic clearance. Preclinical studies have shown robust anti-tumor activity and a promising safety profile. Currently in Phase 1 clinical testing in China, NextCure plans to start clinical trials in the U.S. in the third quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL9hV701:1","article_id":"2543767133","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543767133","pubTimestamp":1750072021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited, has entered into a license agreement with NextCure, Inc. The agreement grants NextCure global rights, excluding the Greater China region, to SIM0505, a novel antibody-drug conjugate targeting CDH6 for the treatment of solid tumors. SIM0505 features Simcere Zaiming's proprietary TOPO isomerase 1 inhibitor, designed for broad anti-tumor activity with high systemic clearance. Preclinical studies have shown robust anti-tumor activity and a promising safety profile. Currently in Phase 1 clinical testing in China, NextCure plans to start clinical trials in the U.S. in the third quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1191":"制药","NXTC":"Nextcure Inc.","BK4139":"生物科技","BK1583":"高瓴概念"},"translate_title":"海南先声再明与NextCure签订创新癌症治疗全球权利许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9,"NXTC":0.9},"content_text":"Hainan Simcere Zaiming Enters License Agreement with NextCure for Global Rights to Innovative Cancer Treatment\n    \n\n        Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited, has entered into a license agreement with NextCure, Inc. The agreement grants NextCure global rights, excluding the Greater China region, to SIM0505, a novel antibody-drug conjugate targeting CDH6 for the treatment of solid tumors. SIM0505 features Simcere Zaiming's proprietary TOPO isomerase 1 inhibitor, designed for broad anti-tumor activity with high systemic clearance. Preclinical studies have shown robust anti-tumor activity and a promising safety profile. Currently in Phase 1 clinical testing in China, NextCure plans to start clinical trials in the U.S. in the third quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}